Pathological interplay of NF-κB and M1 macrophages in chronic inflammatory lung diseases

Area of Science:

• Immunology
• Molecular Biology
• Pulmonology

Background:

• Inflammatory lung diseases, including asthma, COPD, and pulmonary fibrosis, are significantly influenced by the nuclear factor kappa B (NF-κB) signaling pathway.
• M1 macrophage polarization plays a critical role in the pathology of these chronic inflammatory lung conditions.
• The interplay between NF-κB activation and M1 macrophages drives pro-inflammatory mediator release and tissue damage.

Purpose of the Study:

• To elucidate the molecular mechanisms linking NF-κB signaling and M1 macrophage polarization in inflammatory lung diseases.
• To review current and emerging therapeutic strategies targeting the NF-κB/M1 macrophage axis.
• To highlight the potential of precision medicine approaches for managing complex inflammatory lung conditions.

Main Methods:

• Review of existing literature on NF-κB signaling, macrophage polarization, and inflammatory lung diseases.
• Analysis of molecular interactions and cross-talk between signaling pathways (MAPK, JAK-STAT, PI3K-Akt) and NF-κB.
• Evaluation of therapeutic interventions, including small molecules, natural compounds, RNA-based systems, and nanoparticle delivery.

Main Results:

• NF-κB activation in macrophages leads to the production of pro-inflammatory cytokines (TNFα, IL6, IL1β) and reactive oxygen species (ROS), exacerbating airway remodeling and fibrosis.
• Cross-talk with MAPK, JAK-STAT, and PI3K-Akt pathways amplifies NF-κB's detrimental effects on lung disease progression.
• Therapeutic inhibition of NF-κB and modulation of macrophage polarization show promise in attenuating inflammation and promoting repair.

Conclusions:

• Targeting the NF-κB signaling pathway and M1 macrophage polarization presents a viable strategy for treating inflammatory lung diseases.
• Precision medicine approaches, utilizing natural compounds, RNA-based therapies, and nanoparticles, offer novel therapeutic avenues.
• Further research is essential to overcome challenges in specificity, minimize side effects, and optimize delivery for effective targeted therapies.